NEW WEBSITE ONLINE!
We are happy to announce that we have launched a new web page for OYSTA – an innovative healthcare brand which we have developed together with our partner Ondosis.
With OYSTA, we aim to revolutionize the way how patients take their medicines by combining pharmaceuticals with e-health technology to enable intuitive, precise, and flexible dosing.
The new web page provides an overview of the purpose, function, and value of the unique product concept. For our community we have already recorded a sneak preview, but see for yourself and learn more about OYSTA on www.oysta-health.com.
About TIEFENBACHER GROUP – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our goal is to improve patients’ lives by making pharmaceuticals more affordable, more available and better than ever before.
For further information about our better healthcare solution and in-house capabilities to develop and commercialize pharmaceuticals products including high-potent for global markets please contact Tiefenbacher Group: info@aet.eu
Successful Approval of manufacturing and laboratory facilities by Saudi Food and Drug Authority
New site approval! We are happy to announce that our manufacturing and laboratory facilities for oral solids at AET Laboratories in Hyderabad (India) have been successfully registered by the Saudi Food and Drug Authority.
The registration is a great door opener for the full GCC region. It is an important addition to our existing European and international certifications (like the US FDA approval) and follows Tiefenbacher Group´s strategy to make our high-quality pharmaceuticals better available worldwide!
About TIEFENBACHER GROUP – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our goal is to improve patients’ lives by making pharmaceuticals more affordable, more available and better than ever before.
For further information about our better healthcare solution and in-house capabilities to develop and commercialize pharmaceuticals products including high-potent for global markets please contact Tiefenbacher Group: info@aet.eu
TIEFENBACHER GROUP IS COMMITTED TO BECOMING CLIMATE NEUTRAL
We are pleased to share that TIEFENBACHER GROUP is committed to becoming climate neutral by the end of 2025*. As a value-driven healthcare company, dedicated to improving the life of patients worldwide, we recognize the importance of taking action to address the urgent climate crisis we face today. To achieve this goal, we are implementing a comprehensive sustainability strategy that includes the following measures, among others:
As our biggest driver of the carbon footprint is energy consumption, large-scale solar panels will be installed on our manufacturing facilities in Cyprus and India. Any electricity that cannot be produced in-house and must be purchased will be purely green electricity. In addition, we are implementing energy saving and efficiency measures – especially at our production sites. Furthermore, all company vehicles will be exclusively electric in the future. With these measures, we will already achieve a great interim goal: reducing our emissions by 80% by January 2024.
We believe that this is not only the right thing to do for the planet but also the right thing to do for our business. Being commercially successful and operating responsibly by becoming climate neutral is how we generate sustainable returns. We look forward to sharing more updates on our progress towards this important goal in the coming months and years.
*Scope 1 and 2 according to GHG as well as business travel and employee commuting
About TIEFENBACHER GROUP – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our goal is to improve patients’ lives by making pharmaceuticals more affordable, more available and better than ever before.
For further information about our better healthcare solution and in-house capabilities to develop and commercialize pharmaceuticals products including high-potent for global markets please contact Tiefenbacher Group: info@aet.eu
RENOVATING HEADQUARTERS IN HAMBURG
Did you know that Tiefenbacher Group is currently renovating its headquarters in Hamburg, Germany? We are excited to share the first results of the restructuring and are pleased to bring the first changes to life.
The newly designed building will be a modern and innovative workspace that reflects our culture of entrepreneurship, professional excellence, and openness. The open-floor concept promotes creativity, collaboration, and teamwork among our employees. We believe that the new space, right on the banks of the river Elbe, provides a great working environment that supports the growth and wellbeing of our employees at the same time.
Watch our short video to see the first changes. We´ll keep you posted on the progress and look forward to welcoming you to our new office space soon!
About TIEFENBACHER GROUP – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our goal is to improve patients’ lives by making pharmaceuticals more affordable, more available and better than ever before.
For further information about our better healthcare solution and in-house capabilities to develop and commercialize pharmaceuticals products including high-potent for global markets please contact Tiefenbacher Group: info@aet.eu
TIEFENBACHER GROUP AT DCAT 2023 – THANKS FOR MEETING US IN NEW YORK CITY!
DCAT week – one of the world´s most important pharma events – has just come to an end. It was four very successful and inspiring days for TIEFENBACHER GROUP in New York City. What a pleasure to present our latest product portfolio and innovations and to connect with existing and potential new partners. Check out our short video to get some impressions!
About TIEFENBACHER GROUP – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our goal is to improve patients’ lives by making pharmaceuticals more affordable, more available and better than ever before.
For further information about our better healthcare solution and in-house capabilities to develop and commercialize pharmaceuticals products including high-potent for global markets please contact Tiefenbacher Group: info@aet.eu
NEW MARKET LAUNCH: TIEFENBACHER PHARMACEUTICALS SUCCESSFULLY LAUNCHES THE ANTIHISTAMINE BILASTINE FOR A MARKET ENTRY AS OVER-THE-COUNTER (OTC) MEDICINE IN GERMANY
As the allergy season is starting, we at TIEFENBACHER PHARMACEUTICALS are thrilled to announce that we have successfully prepared the launch of the antihistamine Bilastine for a market entry as Over-the-counter (OTC) medicine in Germany.
Bilastine is an innovative anti-allergy medicine for patients suffering from allergic symptoms, such as hay fever and urticaria. It belongs to the non-sedating second-generation antihistamines. The 20 mg tablets have been developed in TIEFENBACHER GROUP´s own laboratories and will be marketed by our partner, a well-known international pharmaceutical company.
With this market entry we enable patients in Germany a better access to an important medicine which is currently the only product of this type available in pharmacies without a prescription needed. Further launches in European markets are planned soon.
AET TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes affordable high-quality healthcare solutions as well as medical devices worldwide. We provide over 180+ pharmaceuticals products across various therapeutic categories in 40+ dosage forms. With our in-house product development, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines including high-potent for global markets.
For more information around our finished dosage forms and healthcare solutions, please contact AET Tiefenbacher Pharmaceuticals: info@aet.eu or please visit us on: www.aet.eu
About TIEFENBACHER GROUP – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.
TIEFENBACHER GROUPS MANUFACTURING SITES HAVE BEEN SUCCESSFULLY REGISTERED BY THE UNITED ARAB EMIRATES MINISTRY OF HEALTH
We are excited to announce that our two manufacturing sites at AET Laboratories in Hyderabad (India) and at Delorbis in Lefkosia (Cyprus) have been successfully registered by the United Arab Emirates Ministry of Health! The approvals are based on our existing European and international certifications and follow Tiefenbacher Group´s strategy to make our high-quality pharmaceuticals better available worldwide!
About TIEFENBACHER GROUP – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our goal is to improve patients’ lives by making pharmaceuticals more affordable, more available and better than ever before.
For further information about our better healthcare solution and in-house capabilities to develop and commercialize pharmaceuticals products including high-potent for global markets please contact Tiefenbacher Group: info@aet.eu
World Cancer Day 2023
We are approaching World Cancer Day 2023. Cancer has a global impact of around 20 million new cases each year, remaining a major public health challenge. In the fight against this disease, we at TIEFENBACHER GROUP are committed to deliver better affordable medicines for cancer patients around the world.
Hereby we are always aiming to improve patients’ lives by developing added value medicines with a better posology, additional strengths, suitable fixed dosage combinations, or personalized therapies by combining medicines with smart e-health solutions – just to name a few of our differentiated and innovative product solutions.
TIEFENBACHER PHARMACEUTICALS (FDF business unit of TIEFENBACHER GROUP) has already 25 leading highly potent cancer drugs in its launch pipeline which are planned to be developed and manufactured in our new state-of-the-art high potent facilities in Hyderabad, India.
AET TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes affordable high-quality healthcare solutions as well as medical devices worldwide. We provide over 180+ pharmaceuticals products across various therapeutic categories in 40+ dosage forms. With our in-house product development, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines including high-potent for global markets.
For more information around our finished dosage forms and healthcare solutions, please contact AET Tiefenbacher Pharmaceuticals: info@aet.eu or please visit us on: www.aet.eu
About TIEFENBACHER GROUP – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.
TIEFENBACHER GROUP WISHES A HEALTHY NEW YEAR 2023
From all over the world, we wish you a happy and healthy New Year 2023!
In order to serve more than 80 national markets in the best possible way for our partners, we are particularly proud to have so many different nationalities and cultures at TIEFENBACHER GROUP. Watch our colleagues from our various locations sharing short New Year’s greetings in their respective national languages with you.
For information about our product portfolio and innovative health care solutions please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com
About TIEFENBACHER GROUP – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our goal is to improve patients’ lives by making pharmaceuticals more affordable, more available and better than ever before.
For further information about our better healthcare solution and in-house capabilities to develop and commercialize pharmaceuticals products including high-potent for global markets please contact Tiefenbacher Group: info@aet.eu
NEW MARKET LAUNCH: TIEFENBACHER PHARMACEUTICALS SUCCESSFULLY LAUNCHES GENERIC VERSION OF THE PSORIASIS MEDICATION APREMILAST IN CANADA
We at TIEFEENBACHER PHARMACEUTICALS strive to make our high-quality medicines better affordable and better available for patients around the world. That´s why we are excited to share that we have successfully prepared the launch of the generic version of Apremilast for a market entry on day one after patent expiration in Canada.
Apremilast is indicated for the treatment of adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, and oral ulcers. We are standing out in launching the only generic version of Apremilast in the form of a starter kit (10 mg, 20 mg, and 30 mg) additionally to bottles of 30 mg tablets. This allows the product to be taken gradually to the recommended dosage, facilitating the work of physicians and pharmacists and improving the patient experience.
The product has been developed and produced in TIEFENBACHER GROUP´s own state-of-the-art facilities in India and is marketed by our partner, a well-established Canadian pharmaceutical company.
With this early market entry TIEFENBACHER PHARMACEUTICALS achieves significant savings for the international health care systems and enables patients in Canada a better affordable access to a life-improving treatment.
AET TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes affordable high-quality healthcare solutions as well as medical devices worldwide. We provide over 180+ pharmaceuticals products across various therapeutic categories in 40+ dosage forms. With our in-house product development, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines including high-potent for global markets.
For more information around our finished dosage forms and healthcare solutions, please contact AET Tiefenbacher Pharmaceuticals: info@aet.eu or please visit us on: www.aet.eu
About TIEFENBACHER GROUP – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.
Further information about our better healthcare solution and in-house capabilities to develop and commercialize pharmaceuticals products including high-potent for global markets can be found on can be found on www.tiefenbacher.com or you can contact us info@aet.eu
